AbbVie outdoes rumored J&J bid with $21bn Pharmacyclics buy
This article was originally published in Scrip
AbbVie swooped in to buy Pharmacyclics for $21bn on 4 March after several days of speculation that the Sunnyvale, California-based biopharmaceutical firm would be acquired by its Imbruvica (ibrutinib) development partner Johnson & Johnson for as much as $19bn.
You may also be interested in...
AbbVie/Pharmacyclics executives Danelle James and Mohamed Zaki, in an interview at ASH, discussed Imbruvica's worth in chemo-free settings and noted additional value that could be created with shorter durations of treatment in combination regimens.
Analysts generally were not surprised that Imbruvica plus R-CHOP did not provide a significant benefit versus R-CHOP alone in a hard-to-treat type of non-Hodgkin lymphoma. The failure leaves an opening for competitors, such as Celgene's Revlimid, which will soon have data in this indication.
Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.